Abstract: Interferon-?-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C—X—C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.

Abstract: Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the ?-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.

Abstract: Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the ?-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.

Abstract: A stud tensioner for tensioning the upright studs which secure the head to a reactor pressure vessel is suspended by a motor operated hoist from a motor operated trolley mounted on a circular rail supported above the studs. A single operator operates the motor operated hoist and motor operated trolley, and manually radially fine aligns the stud tensioner for engagement with a stud through a control handlebar. A pair of side-by-side switches adjacent a first hand grip at one end of the handlebar enable the operator to operate the trolley to move the stud tensioner left or right, while vertically aligned switches adjacent a second hand grip at the other end of the handlebar are used to operate the hoist to raise and lower the stud tensioner. Simultaneously, the operator can radially maneuver the stud tensioner by applying force through the handlebar. An adjustable mount allows the handlebar to be rotated about a horizontal pivot axis and locked into a selected angular position relative to the tensioner.

Abstract: Process and apparatus are disclosed for removing and replacing the hold down beams of fluid circulating jet pumps mounted in a nuclear reactor. The disclosed process and apparatus are operable from a position such as the refueling bridge remote from the reactor and while the refueling cavity surrounding the reactor is flooded with moderator fluid.

Abstract: Process and apparatus are disclosed for removing and replacing the hold down beams of fluid circulating jet pumps mounted in a nuclear reactor. The disclosed process and apparatus are operable from a position such as the refueling bridge remote from the reactor and while the refueling cavity surrounding the reactor is flooded with moderator fluid.